Tandem Diabetes Care Shares Rise 8% on FDA Approval of Tubeless Insulin Pump
TNDM Tandem Diabetes Care Inc
$20.07 +14.62%
View chart & analysis → - 1Tandem Diabetes Care shares rose 8%.
- 2The Tandem Mobi insulin pump received FDA approval to operate as a tubeless automated insulin delivery system wearable for up to 7 days.
- 3The company plans a nationwide commercial launch of new cartridges and infusion sets in the first half of 2027.
So what's the key point?
Tandem Diabetes Care received approval for a device that delivers insulin without tubes. Shares rose 8% following this news.
Source Investing.com · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.